Skip Navigation


Lance D. Miller, Ph.D.Wake Forest School of Medicine

Lance D. Miller, Ph.D.

Core Director,
Associate Professor,

Clinical Interests

, Cancer Genetics, Breast Cancer

Contact Information

Academic: 336-716-6017 | Department: 336-716-6017


Media Medical Expert »

Education & Training

  • B.S., University of North Carolina-Chapel Hill, 1992
  • M.S., East Carolina University, 1995
  • Ph.D., University of North Carolina-Chapel Hill, 2001
Lance D. Miller, Ph.D.

Lance D. Miller, Ph.D.

Core Director, Comprehensive Cancer Center
Associate Professor, Cancer Biology
Office of Women in Medicine and Science

Research Interests

Breast Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Oligonucleotide Array Sequence Analysis; Prognosis
More »

Contact Information

Academic: 336-716-6017 | Department: 336-716-6017


Media Medical Expert »

Recent Publications

Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system?. Yang M, Forbes ME, Bitting RL, O'Neill SS, Chou PC, Topaloglu U, Miller LD, Hawkins GA, Grant SC, DeYoung BR, Petty WJ, Chen K, Pasche BC, Zhang W.. Ann Oncol. 2018;29(2):311-323.

Early and locally advanced metaplastic breast cancer: presentation and survival by receptor status in surveillance, epidemiology, and end results (SEER) 2010-2014. Schroeder MC, Rastogi P, Geyer CE Jr, Miller LD, Thomas A.. Oncologist. 2018;23(4):481-488.

A phase I study of CPI-613 in combination with high dose cytarabine and mitoxantrone for relapsed or refractory acute myeloid leukemia. Pardee TS, Anderson RG, Pladna KM, Isom S, Ghiraldeli LP, Miller LD, Chou JA, Jin G, Zhang W, Ellis LR, Berenzon D, Howard DS, Hurd D, Manuel M, Dralle S, Lyerly S, Powell BL.. Clin Cancer Res. 2018;():.

Exosomal microRNA profiling to identify hypoxia-related biomarkers in prostate cancer. Panigrahi GK, Ramteke A, Birks D, Abouzeid Ali HE, Venkataraman S, Agarwal C, Vibhakar R, Miller LD, Agarwal R, Abd Elmageed ZY, Deep G.. Oncotarget. 2018;9(17):.

Multimodal assessment of estrogen receptor mRNA profiles to quantify estrogen pathway activity in breast tumors. Muthukaruppan A, Lasham A, Woad KJ, Black MA, Blenkiron C, Miller LD, Harris G, McCarthy N, Findlay MP, Shelling AN, Print CG.. Clin Breast Cancer. 2017;17(2):139-153.

APOL1 renal-risk variants induce mitochondrial dysfunction. Ma L, Chou JW, Snipes JA, Bharadwaj MS, Craddock AL, Cheng D, Weckerle A, Petrovic S, Hicks PJ, Hemal AK, Hawkins GA, Miller LD, Molina AJ, Langefeld CD, Murea M, Parks JS, Freedman BI.. J Am Soc Nephrol. 2017;28(4):1093-1105.

Iron addiction: a novel therapeutic target in ovarian cancer. Basuli D, Tesfay L, Deng Z, Paul B, Yamamoto Y, Ning G, Xian W, McKeon F, Lynch M, Crum CP, Hegde P, Brewer M, Wang X, Miller LD, Dyment N, Torti FM, Torti SV.. Oncogene. 2017;36(29):4089-4099.

Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. Hendrickx W, Simeone I, Anjum S, Mokrab Y, Bertucci F, Finetti P, Curigliano G, Seliger B, Cerulo L, Tomei S, Delogu LG, Maccalli C, Wang E, Miller LD, Marincola FM, Ceccarelli M, Bedognetti D.. Oncoimmunology. 2017;6(2):e1253654.

Genomic testing using cytology vs surgical specimens: a comparative study [abstract]. Steele RM, Topaloglu U, Miller LD, Zhang W, Pasche B, DeYoung BR, Qaseni SA [sic] Qasem SA.. Mod Pathol. 2017;30(Suppl 2):520A.

Genomic testing using cytology vs surgical specimens: a comparative study [abstract]. Steele RM, Tapaloglu U, Miller LD, Zhang W, Pasche B, DeYoung BR, Qasem SA.. Lab Invest. 2017;97(Suppl 1):520A.

Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. Alistar A, Morris BB, Desnoyer R, Klepin HD, Hosseinzadeh K, Clark C, Cameron A, Leyendecker J, D'Agostino R Jr, Topaloglu U, Boteju LW, Boteju AR, Shorr R, Zachar Z, Bingham PM, Ahmed T, Crane S, Shah R, Migliano JJ, Pardee TS, Miller L,.. Lancet Oncol. 2017;18(6):770-778.

Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. Gnjatic S, Bronte V, Brunet LR, Butler MO, Disis ML, Galon J, Hakansson LG, Hanks BA, Karanikas V, Khleif SN, Kirkwood JM, Miller LD, Schendel DJ, Tanneau I, Wigginton JM, Butterfield LH.. J Immunother Cancer. 2017;5():44.

Mutational landscapes of smoking-related cancers in Caucasians and African Americans: precision oncology perspectives at Wake Forest Baptist Comprehensive Cancer Center. Kytola V, Topaloglu U, Miller LD, Bitting RL, Goodman MM, D Agostino RB Jr, Desnoyers RJ, Albright C, Yacoub G, Qasem SA, DeYoung B, Thorsson V, Shmulevich I, Yang M, Shcherban A, Pagni M, Liu L, Nykter M, Chen K, Hawkins GA, Grant SC,.. Theranostics. 2017;7(11):2914-2923.

Determination of tumor gene expression in non-small cell lung cancer patients who develop brain metastasis diagnosis: analysis of a prospective trial [abstract]. Dohm AE, Su J, McTyre E, Soike M, Miller LD, Petty WJ, Xing F, Lo HW, Metheny-Barlow L, Watabe K, Chan MD, Ruiz J, Pasche B.. Int J Radiat Oncol Biol Phys. 2017;99(2 Suppl):E453.

EGFR and HER2 signaling in breast cancer brain metastasis. Sirkisoon SR, Carpenter RL, Rimkus T, Miller L, Metheny-Barlow L, Lo HW.. Front Biosci (Elite Ed). 2016;8():245-263.

ERRalpha is a marker of tamoxifen response and survival in triple-negative breast cancer. Manna S, Bostner J, Sun Y, Miller LD, Alayev A, Schwartz NS, Lager E, Fornander T, Nordenskjold B, Yu JJ, Stal O, Holz MK.. Clin Cancer Res. 2016;22(6):1421-1431.

Yin Yang 1 promotes mTORC2-mediated AKT phosphorylation. Zhang Q, Wan M, Shi J, Horita DA, Miller LD, Kute TE, Kridel SJ, Kulik G, Sui G.. J Mol Cell Biol. 2016;8(3):232-243.

Prognostic molecular subtypes of low-grade cancer of the appendix. Levine EA, Votanopoulos KI, Qasem SA, Philip J, Cummins KA, Chou JW, Ruiz J, D'Agostino R, Shen P, Miller LD.. J Am Coll Surg. 2016;222(4):493-503.

Disentangling the relationship between tumor genetic programs and immune responsiveness. Bedognetti D, Hendrickx W, Ceccarelli M, Miller LD, Seliger B.. Curr Opin Immunol. 2016;39():150-158.

Effects of pubertal exposure to dietary soy on estrogen receptor activity in the breast of cynomolgus macaques. Dewi FN, Wood CE, Willson CJ, Register TC, Lees CJ, Howard TD, Huang Z, Murphy SK, Tooze JA, Chou JW, Miller LD, Cline JM.. Cancer Prev Res (Phila Pa). 2016;9(5):385-395.

Immunogenic subtypes of breast cancer delineated by gene classifiers of immune responsiveness. Miller LD, Chou JA, Black MA, Print C, Chifman J, Alistar A, Putti T, Zhou X, Bedognetti D, Hendrickx W, Pullikuth A, Rennhack J, Andrechek ER, Demaria S, Wang E, Marincola FM.. Cancer Immunol Res. 2016;4(7):600-610.

Gene expression signatures of effector immune cell abundance are significantly associated with recurrence risk in colon cancer [abstract]. Alistar AT, Chifman J, D'Agostino R Jr, Miller LD.. Cancer Immunol Res. 2016;4(1 Suppl):A011.

Gene variability between perineural-positive and perineural-negative squamous cell skin cancers. Mays AC, Chou J, Craddock AL, Miller L, Browne JD.. Anticancer Res. 2016;36(8):4007-4011.

Conservation of immune gene signatures in solid tumors and prognostic implications. Chifman J, Pullikuth A, Chou JW, Bedognetti D, Miller LD.. BMC Cancer. 2016;16(1):911.

Hepcidin regulation in prostate and its disruption in prostate cancer. Tesfay L, Clausen KA, Kim JW, Hegde P, Wang X, Miller LD, Deng Z, Blanchette N, Arvedson T, Miranti CK, Babitt JL, Lin HY, Peehl DM, Torti FM, Torti SV.. Cancer Res. 2015;75(11):2254-2263.

A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer. Cowherd S, Miller LD, Melin SA, Akman S, Isom S, Cole J, Pullikuth A, Lawrence JA.. Cancer Biol Ther. 2015;16(5):678-683.

Systems biology approach to studying proliferation-dependent prognostic subnetworks in breast cancer. Song Q, Wang H, Bao J, Pullikuth AK, Li KC, Miller LD, Zhou X.. Sci Rep. 2015;5():12981.

Prognostic and predictive immune gene signatures in breast cancer. Bedognetti D, Hendrickx W, Marincola FM, Miller LD.. Curr Opin Oncol. 2015;27(6):433-444.

Genomic predictors of patterns of progression in glioblastoma and possible influences on radiation field design. Holmes JA, Paulsson AK, Page BR, Miller LD, Liu W, Xu J, Hinson WH, Lesser GJ, Laxton AW, Tatter SB, Debinski W, Chan MD.. J Neurooncol. 2015;124(3):447-453.

Molecular subtyping in advanced non-small cell lung cancer, a minimally invasive strategy with small volume fine needle aspirates [abstract]. Hansen K, Miller L, Dotson T, Bellinger C, Parks G, Cappellari J, Clark H, Howard C, Bolemon B, Petty WJ, Craddock L, Ruiz J.. J Thorac Oncol. 2015;10(9 Suppl 2):S701.

IRP2 regulates breast tumor growth. Wang W, Deng Z, Hatcher H, Miller LD, Di X, Tesfay L, Sui G, D'Agostino RB Jr, Torti FM, Torti SV.. Cancer Res. 2014;74(2):497-507.

Comparison of clinical outcomes and genomic characteristics of single focus and multifocal glioblastoma. Paulsson AK, Holmes JA, Peiffer AM, Miller LD, Liu W, Xu J, Hinson WH, Lesser GJ, Laxton AW, Tatter SB, Debinski W, Chan MD.. J Neurooncol. 2014;119(2):429-435.

A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies. Pardee TS, Lee K, Luddy J, Maturo C, Rodriguez R, Isom S, Miller LD, Stadelman KM, Levitan D, Hurd D, Ellis LR, Harrelson R, Manuel M, Dralle S, Lyerly S, Powell BL.. Clin Cancer Res. 2014;20(20):5255-5264.

DEAD-box helicase DP103 defines metastatic potential of human breast cancers. Shin EM, Hay HS, Lee MH, Goh JN, Tan TZ, Sen YP, Lim SW, Yousef EM, Ong HT, Thike AA, Kong X, Wu Z, Mendoz E, Sun W, Salto-Tellez M, Lim CT, Lobie PE, Lim YP, Yap CT, Zeng Q, Sethi G, Lee MB, Tan P, Goh BC, Miller LD, Thiery JP, Zhu T, Gaboury L,.. J Clin Invest. 2014;124(9):3807-3824.

Genomic predictors of infield and marginal failure for glioblastoma treated with concurrent radiation therapy and temozolomide: a step towards personalized radiation fields? [abstract]. Holmes JA, Paulsson A, Peiffer AM, Miller LD, Xu J, Hinson WH, Lesser GJ, Tatter SB, Debinski W, Chan MD.. Int J Radiat Oncol Biol Phys. 2014;90(Suppl 1):S291-S292.

Dual roles for immune metagenes in breast cancer prognosis and therapy prediction. Alistar A, Chou JW, Nagalla S, Black MA, D'Agostino R Jr, Miller LD.. Genome Med. 2014;6(10):80.

Functional presence of M2 macrophage markers in GBM tumor cells [abstract]. Debinski W, Rodriguez A, Gibo D, Tatter SB, Mott R, Lively M, Miller L, Seals DF.. Neuro Oncol. 2014;16(Suppl 3):.

Sal-like protein 4 (SALL4), a stem cell biomarker in liver cancers. Oikawa T, Kamiya A, Zeniya M, Chikada H, Hyuck AD, Yamazaki Y, Wauthier E, Tajiri H, Miller LD, Wang XW, Reid LM, Nakauchi H.. Hepatology. 2013;57(4):1469-1483.

Irp2 regulates tumor growth in breast cancer [abstract]. Wang W, Deng ZY, Hatcher H, Miller L, Di XM, Tesfay L, D'Agostino RB Jr, Torti S, Torti F.. Am J Hematol. 2013;88(5):E15.

Prognostic value of the hDMP1-ARF-Hdm2-p53 pathway in breast cancer. Maglic D, Zhu S, Fry EA, Taneja P, Kai F, Kendig RD, Sugiyama T, Miller LD, Willingham MC, Inoue K.. Oncogene. 2013;32(35):4120-4129.

Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis. Nagalla S, Chou JW, Willingham MC, Ruiz J, Vaughn JP, Dubey P, Lash TL, Hamilton-Dutoit SJ, Bergh J, Sotiriou C, Black MA, Miller LD.. Genome Biol. 2013;14(4):R34.

The regulation of SOX7 and its tumor suppressive role in breast cancer. Stovall DB, Wan M, Miller LD, Cao P, Maglic D, Zhang Q, Stampfer MR, Liu W, Xu J, Sui G.. Am J Pathol. 2013;183(5):1645-1653.

Fractionated whole brain irradiation modulates Homer1a expression in a brain region specific manner [abstract]. Moore E, Kooshki M, Miller L, Robbins M [deceased].. Cancer Res. 2013;73(8 Suppl 1):A78.

YB-1, the E2F pathway, and regulation of tumor cell growth. Lasham A, Samuel W, Cao H, Patel R, Mehta R, Stern JL, Reid G, Woolley AG, Miller LD, Black MA, Shelling AN, Print CG, Braithwaite AW.. J Natl Cancer Inst. 2012;104(2):133-146.

RAS mutations and oncogenesis: not all RAS mutations are created equally. Miller MS, Miller LD.. Front Genet. 2012;2():100.

Yin Yang 1 contains G-quadruplex structures in its promoter and 5'-UTR and its expression is modulated by G4 resolvase 1. Huang W, Smaldino PJ, Zhang Q, Miller LD, Cao P, Stadelman K, Wan M, Giri B, Lei M, Nagamine Y, Vaughn JP, Akman SA, Sui G.. Nucleic Acids Res. 2012;40(3):1033-1049.

Yin Yang 1 plays an essential role in breast cancer and negatively regulates p27. Wan M, Huang W, Kute TE, Miller LD, Zhang Q, Hatcher H, Wang J, Stovall DB, Russell GB, Cao PD, Deng Z, Wang W, Zhang Q, Lei M, Torti SV, Akman SA, Sui G.. Am J Pathol. 2012;180(5):2120-2133.

Strategies to defeat ketamine-induced neonatal brain injury. Turner CP, Gutierrez S, Liu C, Miller L, Chou J, Finucane B, Carnes A, Kim J, Shing E, Haddad T, Phillips A.. Neuroscience. 2012;210():384-392.

Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells. Caldon CE, Sergio CM, Kang J, Muthukaruppan A, Boersma MN, Stone A, Barraclough J, Lee CS, Black MA, Miller LD, Gee JM, Nicholson RI, Sutherland RL, Print CG, Musgrove EA.. Mol Cancer Ther. 2012;11(7):1488-1499.

Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. Prat A, Parker JS, Fan C, Cheang MC, Miller LD, Bergh J, Chia SK, Bernard PS, Nielsen TO, Ellis MJ, Carey LA, Perou CM.. Ann Oncol. 2012;23(11):2866-2873.

All Publications

For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.

For a list of earlier publications, visit the Carpenter Library Publication Search.

Associate Professor, Cancer Biology

Clinical Interests

, Cancer Genetics, Breast Cancer
Lance D. Miller, Ph.D.

Lance D. Miller, Ph.D.

Core Director, Comprehensive Cancer Center
Associate Professor, Cancer Biology
Office of Women in Medicine and Science

Quick Reference

Request an Appointment
New Patients


Existing patients may contact the clinic directly.
Find a Doctor Ways to Give
Wake Forest Baptist Ranked among Nation’s ‘Best Hospitals’  25 Years in a Row by U.S. News & World ReportComprehensive Cancer Centers National Designation is Renewed2017-2018 Best DoctorsNursing Magnet StatusJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.

© Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC 27157. All Rights Reserved.